Karuna Therapeutics Performance
| KRTXDelisted Stock | USD 203.11 1.46 0.71% |
The company secures a Beta (Market Risk) of 0.15, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Karuna Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Karuna Therapeutics is expected to be smaller as well. Karuna Therapeutics right now secures a risk of 0.0%. Please verify Karuna Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Karuna Therapeutics will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Karuna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Karuna Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 248.6 M |
Karuna |
Karuna Therapeutics Relative Risk vs. Return Landscape
If you would invest 20,311 in Karuna Therapeutics on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Karuna Therapeutics or generate 0.0% return on investment over 90 days. Karuna Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Karuna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Karuna Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Karuna Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Karuna Therapeutics, and traders can use it to determine the average amount a Karuna Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KRTX |
Based on monthly moving average Karuna Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Karuna Therapeutics by adding Karuna Therapeutics to a well-diversified portfolio.
Karuna Therapeutics Fundamentals Growth
Karuna Stock prices reflect investors' perceptions of the future prospects and financial health of Karuna Therapeutics, and Karuna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Karuna Stock performance.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (755.64) % | |||
| Current Valuation | 11.35 B | |||
| Shares Outstanding | 38.2 M | |||
| Price To Earning | (19.88) X | |||
| Price To Book | 10.05 X | |||
| Price To Sales | 19,265 X | |||
| Revenue | 654 K | |||
| EBITDA | (493.08 M) | |||
| Cash And Equivalents | 407.41 M | |||
| Cash Per Share | 13.60 X | |||
| Total Debt | 16.69 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 32.94 X | |||
| Cash Flow From Operations | (385.82 M) | |||
| Earnings Per Share | (11.74) X | |||
| Total Asset | 1.34 B | |||
| Retained Earnings | (997.89 M) | |||
| Current Asset | 6.24 M | |||
| Current Liabilities | 8.73 M | |||
About Karuna Therapeutics Performance
Evaluating Karuna Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Karuna Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Karuna Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.Things to note about Karuna Therapeutics performance evaluation
Checking the ongoing alerts about Karuna Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Karuna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Karuna Therapeutics is not yet fully synchronised with the market data | |
| Karuna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 654 K. Net Loss for the year was (433.68 M) with profit before overhead, payroll, taxes, and interest of 10.64 M. | |
| Karuna Therapeutics currently holds about 407.41 M in cash with (385.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.6. | |
| Over 86.0% of the company shares are owned by institutional investors |
- Analyzing Karuna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Karuna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Karuna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Karuna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Karuna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Karuna Therapeutics' stock. These opinions can provide insight into Karuna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |